Sanger Institute joins Wellcome Leap Global Network dedicated to accelerated breakthroughs in human health
Charter group of 21 world-class institutions representing a network of over 150,000 researchers across six continents sign agreement that sets new bar for fast-paced research and development
The Wellcome Sanger Institute announced today that it has joined the Leap Health Breakthrough Network, a global group of leading academic and research institutions committed to solving the world’s most serious health challenges — such as cancer and infectious diseases — at record speed. Wellcome Leap is a U.S. non-profit organization founded by Wellcome to accelerate innovations that benefit global health.
The COVID-19 pandemic has underscored the importance of tackling urgent, large-scale health challenges quickly and across disciplines, organizations, and borders. It’s imperative that good ideas are identified and funded quickly, and that researchers across many institutions can build solutions together.
Currently it can take as long as a year to finalize a research funding agreement, and when collaboration is required, work frequently cannot begin until all parties are signed — further prolonging the delay. What’s more, key components needed to catalyze innovation sometimes come from individual researchers or smaller institutions that are often left out of major research initiatives. Breakthroughs require momentum, and diverse capabilities, wherever they exist globally.
The Leap Health Breakthrough Network will help eliminate barriers to progress thanks to the first-of-its-kind Master Academic Research Funding Agreement (MARFA), which equitably addresses all terms and conditions, including IP, ownership, and publication. Now that the Sanger Institute has signed the MARFA, it will need to negotiate only the statement of work and cost before funds can be transmitted and work can begin. Often in days, shaving months or more off of development timelines.
“This is a fantastic and innovative initiative that offers huge potential. Global multi-disciplinary collaborations that accelerate science are at the heart of many of the Sanger Institute’s research efforts. We embrace such opportunities to stretch our imagination and explore new scientific possibilities at scale so that new discoveries can be made to support human health. This agreement and Leap are clearly a great way of strengthening and supporting this approach further.”
Martin Dougherty, Chief Operating Officer, Wellcome Sanger Institute
Read more here: www.wellcomeleap.org
Wellcome Leap builds and executes bold, unconventional programs, funded at scale. Programs that aim to deliver breakthroughs in human health over 5 – 10 years. Founded by Wellcome in 2020 as a US nonprofit with initial funding of $300 million, Leap programs target complex human health challenges with the goal of achieving breakthrough scientific and technological solutions. Operating at the intersection of life sciences and engineering, Leap programs require best-in-class, multi-disciplinary, global teams assembled from universities, companies, and nonprofits working together to solve problems that they cannot solve alone.
The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.
Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation. https://wellcome.org/
11 May 2021
Identifying the rise of multi-drug resistant E.coli
Largest genomic study of E.coli has tracked the rise of multi-drug resistance (MDR) in Norway.
30 Apr 2021
New genetic target for blood cancer treatment
Researchers have identified a vulnerability in some cases of acute myeloid leukaemia that could be harnessed for targeted treatment of these ...